表紙
市場調查報告書
商品編碼
954661

婦產科系疾病用醫藥品的全球市場

Pharmaceuticals for Women's Health: Global Markets

出版日期: | 出版商: BCC Research | 英文 140 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球婦產科系疾病用醫藥品市場,預計從2019年到2025年的預測期間以4.7%的年複合成長率成長,從2019年的315億美元成長到2025年412億美元。還有該市場中在預測期間內預計停經後骨質疏鬆症市場以5.7%,更年期障礙市場以5.4%的年複合成長率擴大。

本報告提供全球婦產科系疾病用醫藥品市場的相關調查,市場趨勢及預測,需求,佔有率,開發平台藥物的開發,成長及阻礙因素,各障礙及疾病、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 結論與亮點

第3章 技術和全球市場概要

  • 疾病概要和定義
  • 市場成長要素和機會
    • 高齡女性人口
    • 政府的參及與資金籌措的增加
    • 女性的障礙和治療相關意識的高漲
  • 阻礙市場要素
    • 診斷的不正確
    • 替代治療選擇的利用和生活方式的變化
    • 新的治療方法的不利用性
    • 治療費高

第4章 開發平台的評估與分析

  • 開發平台藥物
    • 骨質疏鬆症治療藥開發平台概要
  • 後期階段的開發平台藥物
    • Relugolix(Myovant Sciences)
    • Proellex(Repros Therapeutics)

第5章 法律規範

  • 法規概要
    • 美國
    • 加拿大
    • 歐洲
    • 日本
  • 價格與償付概要

第6章 市場明細:各障礙、疾病

  • 簡介
  • 閉經
    • 概況
    • 症狀
    • 危險因素
    • 流行病學與經濟負擔
    • 診斷
    • 治療
    • 市場規模與預測
  • 停經後骨質疏鬆症
  • 子宮內膜異位症
  • 多囊性卵巢症候群(PCOS)
  • 妊娠障礙、管理
  • 其他

第7章 市場明細:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 其他亞太地區
  • 南美
  • 中東和非洲

第8章 競爭情形主要的發展

  • 市場參與企業與策略
  • 專利分析
    • 主要的專利
  • 主要的發展
    • 合併和收購
    • 創新的產品的開發/新產品的銷售
    • 契約,合作,聯盟
  • 主要的產品

第9章 企業簡介

  • ABBVIE INC.
  • ALLERGAN PLC
  • AMGEN INC.
  • BAYER AG
  • 第一三共株式會社
  • ELI LILLY AND CO.
  • JOHNSON & JOHNSON INC.
  • MERCK & CO. INC.
  • MERCK KGAA
  • NOVO NORDISK
  • PFIZER INC.

第10章 附錄:詞彙表和簡稱

  • 報告所使用的簡稱
目錄
Product Code: PHM203B

Highlights:

The global market for women’s health therapeutics should grow from $31.5 billion in 2019 to $41.2 billion by 2025, at a compound annual growth rate (CAGR) of 4.7% for the period of 2019-2025.

Postmenopausal osteoporosis market should grow from $9.4 billion in 2019 to $13.0 billion by 2025 at a CAGR of 5.7% through 2025.

Menopause market should grow from $5.7 billion in 2019 to $7.7 billion by 2025 at a CAGR of 5.4% through 2025.

Report Scope:

While women's health encompasses several health issues, this report will focus on menopause-related disorders, postmenopausal osteoporosis, endometriosis, polycystic ovarian syndrome and pregnancy disorders. This report does not focus on drugs for infertility, diagnostic and drug technologies for breast cancer or therapies and diagnostics for ovarian cancer.

Report Includes:

  • 54 tables
  • Detailed overview of the global markets for pharmaceuticals for women's health and identification of the main women's health disorders
  • Analyses of market trends, with data from 2019, estimates for 2020 and projections of compound annual growth rates (CAGRs) through 2025
  • Evaluation of the impact of demographic, economic and other factors that will drive future demand in the women's health therapeutics market
  • A look at the unmet needs in women's health therapeutics and details of the promising new drugs and therapies that are still in development and testing stage
  • Market forecast of the potential drugs in the pipeline, information on late-stage pipeline drugs and overview of osteoporosis drug development
  • Insights into government concerns and initiatives towards women's health
  • Highlights of current and future market potential and a detailed analysis of the current market size, and regulatory scenarios
  • Market share analysis of leading drug manufacturers and detailed coverage of women's health therapeutics industry in terms of different events like mergers and acquisitions, agreements, collaborations, and partnerships
  • Company profiles of the leading suppliers of the industry including AbbVie Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Johnson & Johnson Inc. and Merck KGaA

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Technologies and Global Markets Overview

  • Disease Overview and Definitions
  • Market Driving Factors and Opportunities
    • Aging Female Population
    • Government Involvement and Increased Funding
    • Increasing Awareness Regarding Women's Disorders and Treatments
  • Market Restraints
    • Poor Diagnosis
    • Availability of Alternate Treatment Options and Lifestyle Changes
    • Unavailability of Novel Treatments
    • High Cost of Treatment

Chapter 4: Pipeline Assessment and Analysis

  • Drugs in the Pipeline
    • Overview of Osteoporosis Drug Development Pipeline
  • Late-Stage Pipeline Drugs
    • Relugolix (Myovant Sciences)
    • Proellex (Repros Therapeutics)

Chapter 5: Regulatory Structure

  • Overview of Regulations
    • United States
    • Canada
    • Europe
    • Japan
  • Overview of Pricing and Reimbursement
    • United States
    • Canada
    • Europe
    • Japan

Chapter 6: Market Breakdown by Women's Health Condition, Disorder and Disease

  • Introduction
  • Menopause
    • Overview
    • Symptoms
    • Risk Factors
    • Epidemiology and Economic Burden
    • Diagnosis
    • Treatments
    • Market Size and Forecasts
  • Postmenopausal Osteoporosis
    • Overview
    • Epidemiology and Economic Burden
    • Diagnosis
    • Treatments
    • Market Size and Forecasts
  • Endometriosis
    • Overview
    • Epidemiology and Economic Burden
    • Diagnosis
    • Treatments
    • Market Size and Forecasts
  • Polycystic Ovary Syndrome (PCOS)
    • Overview
    • Reducing the Risk of PCOS
    • Epidemiology and Economic Burden
    • Diagnosis
    • Treatments
    • Market Size and Forecasts
  • Pregnancy Disorders and Management
    • Overview
    • Market Size and Forecasts
  • Others
    • Overview
    • Market Size and Forecasts

Chapter 7: Market Breakdown by Region

  • Introduction
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • South America
  • Middle East and Africa

Chapter 8: Competitive Landscape and Key Developments

  • Market Players and Strategies
  • Patent Analysis
    • Key Patents
  • Key Developments
    • Mergers and Acquisitions
    • Development of Innovative Products/Novel Product Launch
    • Agreements, Collaborations and Partnerships
  • Key Products

Chapter 9: Company Profiles

  • ABBVIE INC.
  • ALLERGAN PLC
  • AMGEN INC.
  • BAYER AG
  • DAIICHI SANKYO CO. LTD.
  • ELI LILLY AND CO.
  • JOHNSON & JOHNSON INC.
  • MERCK & CO. INC.
  • MERCK KGAA
  • NOVO NORDISK
  • PFIZER INC.

Chapter 10: Appendix: Glossary and Acronyms

  • Acronyms Used in the Report

List of Tables

  • Summary Table: Global Market for Women's Health Therapeutics, by Condition/Disorder/Disease, Through 2025
    • Table 1: Life Expectancy at Birth, by Region
    • Table 2: Pipeline Compounds for Endometriosis
    • Table 3: Pipeline Compounds for Uterine Fibroids
    • Table 4: Pipeline Compounds for All Other Indications
    • Table 5: Pipeline Compounds for Osteoporosis
    • Table 6: Description of Relugolix
    • Table 7: Description of Proellex
    • Table 8: Global Market for Women's Health Therapeutics, by Condition/Disorder/Disease, Through 2025
    • Table 9: FDA Approved Estrogen-only Medicines
    • Table 10: FDA-Approved Progestin-Only Medicines
    • Table 11: FDA Approved Combination Estrogen and Progestin Medicines
    • Table 12: FDA Approved Combination Estrogen and Hormone Medicines
    • Table 13: Vagifem (10 mcg), Patent Expiration
    • Table 14: Global Market for Therapeutics for Menopause, by Region, Through 2025
    • Table 15: Prolia/XGEVA (Denosumab) Patent Expiration
    • Table 16: Global Market for Therapeutics for Postmenopausal Osteoporosis, by Region, Through 2025
    • Table 17: Global Market for Therapeutics for Endometriosis, by Region, Through 2025
    • Table 18: Global Market for Therapeutics for Polycystic Ovary Syndrome, by Region, Through 2025
    • Table 19: Global Market for Therapeutics for Pregnancy Disorders and Management, by Region, Through 2025
    • Table 20: Global Market for Therapeutics for Other Types of Women's Health Conditions, Disorders and Diseases, by Region, Through 2025
    • Table 21: Global Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Region, Through 2025
    • Table 22: North American Market for Women's Health Therapeutics, by Condition/Disorder/Disease, Through 2025
    • Table 23: European Market for Therapeutics for Women's Health, by Condition/Disorder/Disease, Through 2025
    • Table 24: Asia-Pacific Market for Women's Health Therapeutics, by Condition/Disorder/Disease, Through 2025
    • Table 25: South American Market for Therapeutics for Women's Health, by Condition/Disorder/Disease, Through 2025
    • Table 26: Middle East and African Market for Women's Health Therapeutics, by Condition/Disorder/Disease, Through 2025
    • Table 27: Company Market Share Analysis, by Indication, 2017
    • Table 28: Tier III Companies
    • Table 29: Patent Review
    • Table 30: Marketed Products for Postmenopausal Osteoporosis
    • Table 31: AbbVie Inc.: Marketed Products
    • Table 32: AbbVie Inc.: Net Revenue, 2017-2019
    • Table 33: Allergan Plc: Marketed Products
    • Table 34: Allergan Plc: Net Revenue, 2017-2019
    • Table 35: Amgen Inc.: Marketed Products, 2016
    • Table 36: Amgen Inc.: Net Revenue, 2017-2019
    • Table 37: Bayer AG: Marketed Products
    • Table 38: Bayer AG: Net Revenue, 2018 and 2019
    • Table 39: Daiichi Sankyo Co. Ltd.: Marketed Products
    • Table 40: Daiichi Sankyo Co. Ltd.: Net Revenue, 2017 and 2018
    • Table 41: Eli Lilly and Co.: Marketed Products
    • Table 42: Eli Lilly and Co.: Net Revenue, 2018 and 2019
    • Table 43: Johnson & Johnson Inc.: Marketed Products, 2020
    • Table 44: Johnson & Johnson Inc.: Net Revenue, 2017-2019
    • Table 45: Merck & Co. Inc.: Marketed Products
    • Table 46: Merck & Co. Inc.: Net Revenue, 2017-2019
    • Table 47: Merck KGaA: Marketed Products
    • Table 48: Novo Nordisk: Marketed Products
    • Table 49: Novo Nordisk: Net Revenue, 2017-2019
    • Table 50: Pfizer Inc.: Marketed Products by Indication, 2020
    • Table 51: Pfizer Inc.: Net Revenue, 2017-2019
    • Table 52: Glossary of Terms Used in Women's Health Therapeutics
    • Table 53: Abbreviations Used in Women's Health Therapeutics

List of Figures

  • Summary Figure: Global Market for Women's Health Therapeutics, by Condition/Disorder/Disease 2019-2025
    • Figure 1: Distribution of Older Population, by Age Group and Sex, 2017
    • Figure 2: Distribution of Older Population, by Age Group and Sex, 2050
    • Figure 3: Funding for Research, by Disease, 2014-2016
    • Figure 4: Funding for Research on Women's Health, 2014-2016
    • Figure 5: Insurance Coverage in The U.S., by Type of Healthcare Provider, 2014
    • Figure 6: Global Market for Women's Health Therapeutics, 2019-2025
    • Figure 7: Global Market Shares of Women's Health Therapeutics, by Condition/Disorder/Disease, 2019
    • Figure 8: Global Market Shares of Women's Health Therapeutics, by Condition/Disorder/Disease, 2025
    • Figure 9: Global Market for Therapeutics for Menopause, 2019-2025
    • Figure 10: Global Market for Therapeutics for Menopause, by Region, 2019-2025
    • Figure 11: Australian Rate of Hospitalization for Osteoporosis, People Aged 50 and Over, 2015-2016
    • Figure 12: Global Market for Therapeutics for Postmenopausal Osteoporosis, 2019-2025
    • Figure 13: Global Market for Therapeutics for Postmenopausal Osteoporosis, by Region, 2019-2025
    • Figure 14: Global Market for Therapeutics for Endometriosis, 2019-2025
    • Figure 15: Global Market for Therapeutics for Endometriosis, by Region, 2019-2025
    • Figure 16: Global Market for Therapeutics for Polycystic Ovary Syndrome, 2019-2025
    • Figure 17: Global Market for Therapeutics for Polycystic Ovary Syndrome, by Region, 2019-2025
    • Figure 18: Global Market for Therapeutics for Pregnancy Disorders and Management, 2019-2025
    • Figure 19: Global Market for Therapeutics for Pregnancy Disorders and Management, by Region, 2019-2025
    • Figure 20: Global Market for Therapeutics for Other Types of Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 21: Global Market for Therapeutics for Other Types of Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 22: Global Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Region, 2019-2025
    • Figure 23: North American Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 24: North American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
    • Figure 25: North American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
    • Figure 26: North American Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
    • Figure 27: U.S. Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 28: Canadian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 29: Mexican Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 30: European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 31: European Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
    • Figure 32: European Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
    • Figure 33: European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
    • Figure 34: U.K. Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 35: German Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 36: French Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 37: Spanish Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 38: Italian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 39: Rest of European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 40: Asia-Pacific Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 41: Asia-Pacific Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
    • Figure 42: Asia-Pacific Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
    • Figure 43: Asia-Pacific Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
    • Figure 44: Chinese Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 45: Japanese Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 46: Indian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 47: South Korean Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 48: Rest of Asia Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 49: South American Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 50: South American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
    • Figure 51: South American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
    • Figure 52: Middle East and African Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
    • Figure 53: Middle East and African Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
    • Figure 54: Middle East and African Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
    • Figure 55: Global Women's Health Therapeutics Market Share Analysis, 2019
    • Figure 56: AbbVie Inc.: Revenue Share, by Region, 2018
    • Figure 57: Allergan Plc: Revenue Share, by Business Segment, 2017
    • Figure 58: Amgen Inc: R&D Expenditures, 2014-2016
    • Figure 59: Amgen Inc.: Revenue Share, by Region, 2018
    • Figure 60: Bayer AG: Revenue Share, by Region, 2018
    • Figure 61: Bayer AG: Revenue Share, by Business Segment, 2018
    • Figure 62: Daiichi Sankyo Co. Ltd.: R&D Expenditures, 2014-2016
    • Figure 63: Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018
    • Figure 64: Eli Lilly and Co.: Revenue Share, by Business Segment, 2018
    • Figure 65: Eli Lilly and Co.: Revenue Share, by Region, 2018
    • Figure 66: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2018
    • Figure 67: Johnson and Johnson Inc.: Revenue Share, by Region, 2018
    • Figure 68: Merck & Co. Inc.: Revenue Share, by Business Segment, 2018
    • Figure 69: Merck & Co. Inc.: Revenue Share, by Region, 2018
    • Figure 70: Novo Nordisk: Revenue Share, by Region, 2018
    • Figure 71: Novo Nordisk: Revenue Share, by Business Segment, 2018
    • Figure 72: Pfizer Inc.: Revenue Share, by Region, 2018
    • Figure 73: Pfizer Inc.: Revenue Share, by Business Segment, 2018